Understanding a clonoSEQ® Report
What does your clonoSEQ report mean?
Adaptive Biotechnologies delivers MRD results from your clonoSEQ test to your doctor as a report. Your doctor considers the information in this report along with your physical examination, your medical history, and other test results and findings.
Be sure to talk with your doctor about the optimal timing for MRD testing with clonoSEQ based on the type of blood cancer you have and your specific treatment plan.
References to “cancer” on this webpage refer specifically to multiple myeloma, CLL, and B-ALL. References to “sample” refer to bone marrow from patients with multiple myeloma or B-ALL and bone marrow or blood from patients with CLL. Talk to your doctor about your options if you have another type of blood cancer and are interested in MRD testing.
See what a clonoSEQ report includes
clonoSEQ is sensitive enough to find a single cancer cell among a million healthy cells, if enough sample material is provided.1
This is a sample report. The information on your clonoSEQ report will be individual to you.
1clonoSEQ MRD Status
A positive (+) result means residual disease was detected. A negative (-) result means residual disease was not detected. Each report will provide your updated MRD status.* You can gain valuable insights about your cancer regardless of whether you have a positive or negative result.
Talk with your doctor about your MRD status to better understand what a positive or negative result means for you and your treatment plan.
*False-positive or false-negative results may occur for reasons including, but not limited to: contamination, technical, and/or biological factors.
This is the amount of cancer cells detected in your sample. This number shows how much disease is present in your sample when it is taken. Your doctor can help put this number into context based on your current phase of care and treatment goals.
A simple graph will show any changes detected in your MRD level over time. Watching these changes may help you and your doctor better understand your response to treatment and track changes in your levels of cancer cells over time.
This page is intended for a US-based audience.
clonoSEQ® is an FDA-cleared test used to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). CLL Clonality (ID) Tests will also produce an IGHV status result, which is provided as a CLIA-validated laboratory developed test (LDT) but which has not been cleared or approved by the FDA. Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.
clonoSEQ is only available by prescription from a licensed healthcare professional. Results may vary. Talk to your healthcare provider to see if clonoSEQ testing is right for you. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.